Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6) > Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6):607-14

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6):607-14

DOI: 10.23736/S0392-0488.17.05778-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Concepts and controversies in the treatment of cutaneous lichen planus

Charles PUZA 1, Adela R. CARDONES 2, 3

1 Duke University School of Medicine, Durham, NC, USA; 2 Department of Dermatology, Duke University Medical Center, Durham, NC, USA; 3 Durham VA Medical Center, Durham, NC, USA


PDF


Cutaneous lichen planus (CLP) is a chronic autoimmune disease classically associated with severely pruritic, polygonal, violaceous, flat-topped papules and plaques. Subtypes such as hypertrophic and bullous lichen planus and lichen planus pigmentosus have been described. Treatment can be challenging, and prospective controlled studies are lacking. Corticosteroids remain the major options for topical and systemic treatment, although some non-steroidal options exist. Phototherapy, especially with narrow band ultraviolet B (NB-UVB), is effective, but caution must be taken because of the risk of keobnerization. Methotrexate and retinoids are an option for extensive disease, and are relatively well tolerated. Other treatments that have been investigated include sulfasalazine, low molecular weight heparin, griseofulvin, hydroxychloroquine, metronidazole and dapsone.


KEY WORDS: Lichen planus follicularis - Therapeutics - Phototherapy

top of page